Avonex®; Betaseron®; Rebif®
Interferon β is a disease-modifying drug currently indicated for treatment of relapsing forms of multiple sclerosis. Its mechanism of action is complex and is presumed to inhibit immune system T-cell activation and migration into the central nervous system as well as modulate the action of some pro-inflammatory proteins (cytokines). There are three FDA approved beta interferons available in the US - Avonex® (INF-β1a), Betaseron® (INF-β1b), and Rebif® (INF-β1a). These medications are administered via injection, and each has been shown to reduce the frequency of MS relapses, reduce MRI evidence of brain lesions, and possibly reduce disability progression.
References and Readings
- National Clinical Advisory Board of the National Multiple Sclerosis Society. (2007). Disease management consensus statement. Retrieved 15 Feb 2010, from http://www.nationalmssociety.org/download.aspx?id=8.